Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, Saro C, García-Sánchez V, Gento E, Bastida G, Gisbert JP, Vera I, Martinez-Montiel P, Garcia-Morán S, Sánchez MC, Mendoza JL. Taxonera C, et al. Among authors: saro c. Aliment Pharmacol Ther. 2011 Feb;33(3):340-8. doi: 10.1111/j.1365-2036.2010.04531.x. Epub 2010 Dec 7. Aliment Pharmacol Ther. 2011. PMID: 21133961
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Taxonera C, et al. Among authors: saro c. Dig Dis Sci. 2015 Oct;60(10):3075-84. doi: 10.1007/s10620-015-3735-4. Epub 2015 Jun 5. Dig Dis Sci. 2015. PMID: 26044830
Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Chaparro M, et al. Among authors: saro c. Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 10.1002/ibd.21758. Epub 2011 May 25. Inflamm Bowel Dis. 2012. PMID: 21618353
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Domènech E, et al. Among authors: saro c. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52. doi: 10.1111/j.1365-2036.2004.02288.x. Aliment Pharmacol Ther. 2004. PMID: 15606397
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Hinojosa J, et al. Among authors: saro c. Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18. doi: 10.1111/j.1365-2036.2006.03232.x. Aliment Pharmacol Ther. 2007. PMID: 17269996 Clinical Trial.
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.
Taxonera C, Barreiro-de-Acosta M, Bastida G, Martinez-Gonzalez J, Merino O, García-Sánchez V, Gisbert JP, Marín-Jiménez I, López-Serrano P, Gómez-García M, Iglesias E, Lopez-Sanroman A, Chaparro M, Saro C, Bermejo F, Pérez-Carazo L, Plaza R, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Taxonera C, et al. Among authors: saro c. J Crohns Colitis. 2016 Jun;10(6):657-62. doi: 10.1093/ecco-jcc/jjw016. Epub 2016 Jan 19. J Crohns Colitis. 2016. PMID: 26786982 Free article.
Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
R-Grau Mdel C, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-Calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-Salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-Sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP. R-Grau Mdel C, et al. Among authors: saro c. Dig Liver Dis. 2016 Jun;48(6):613-9. doi: 10.1016/j.dld.2016.02.012. Epub 2016 Mar 2. Dig Liver Dis. 2016. PMID: 26992847
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP; CONVERT study group from GETECCU. Taxonera C, et al. Among authors: saro c. J Crohns Colitis. 2018 Nov 15;12(11):1270-1279. doi: 10.1093/ecco-jcc/jjy104. J Crohns Colitis. 2018. PMID: 30052856
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.
Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panés J, García-Sánchez V, López-Lasanta M, Pluma A, Codó L, García-Montero A, Manyé J, Gisbert JP, Marsal S, Julià A. Aterido A, et al. Among authors: saro c. Pharmacogenomics J. 2019 Dec;19(6):547-555. doi: 10.1038/s41397-019-0090-4. Epub 2019 May 2. Pharmacogenomics J. 2019. PMID: 31043678
66 results